A 72-year-old woman from Mumbai presents with a 4-week history of recurrent blisters on the lower abdomen, inner thighs, and axillae. She reports that the blisters are preceded by itchy, red papules and urticarial lesions. Histopathology shows subepidermal blister with eosinophil-rich infiltrate in the dermis. Direct immunofluorescence reveals linear IgG and IgE deposition along the basement membrane zone. She has no significant past medical history and denies any medications. What is the most appropriate next step in management?

Explanation

## Management of Bullous Pemphigoid: First-Line Therapy ### Clinical Diagnosis Confirmation **Key Point:** The clinical presentation, histopathology (subepidermal blister with eosinophilic infiltrate), and linear IgG/IgE deposition on DIF are diagnostic of bullous pemphigoid. ### Treatment Algorithm for Bullous Pemphigoid ```mermaid flowchart TD A[Bullous Pemphigoid Diagnosed]:::outcome --> B{Disease Severity?}:::decision B -->|Localized/Mild| C[Potent Topical Corticosteroids]:::action B -->|Generalized/Moderate-Severe| D[Systemic Corticosteroids]:::action D --> E[Prednisolone 0.5-1 mg/kg/day]:::action E --> F[Taper over 3-6 months]:::action F --> G{Steroid-Sparing Agent Needed?}:::decision G -->|Yes| H[Add Steroid-Sparing Agent]:::action H --> I[Azathioprine or Mycophenolate]:::action G -->|No| J[Continue maintenance dose]:::action C --> K{Response in 2-4 weeks?}:::decision K -->|Yes| L[Continue topical therapy]:::action K -->|No| M[Escalate to systemic corticosteroids]:::action ``` ### Rationale for Systemic Corticosteroids | Factor | Consideration | |--------|---------------| | **Disease extent** | Generalized involvement (lower abdomen, thighs, axillae) — not localized | | **Number of lesions** | Recurrent blisters over 4 weeks — suggests moderate-to-severe disease | | **First-line agent** | Systemic corticosteroids are the gold standard for generalized BP | | **Dosing** | Prednisolone 0.5–1 mg/kg/day (typically 40–60 mg/day), then taper | | **Expected response** | New blister formation stops within 1–2 weeks; existing lesions heal over 4–6 weeks | ### Why Topical Corticosteroids Alone Are Insufficient **High-Yield:** Topical corticosteroids are adequate only for **localized disease** (limited to one or two body areas). This patient has widespread, recurrent blisters across multiple sites, requiring systemic therapy. ### Steroid-Sparing Agents (Second-Line) **Clinical Pearl:** Once disease is controlled (usually 2–4 weeks), steroid-sparing agents (azathioprine, mycophenolate mofetil) are added to allow gradual corticosteroid tapering and reduce long-term steroid toxicity. **Mnemonic:** **SPARING agents** = **S**teroid-**P**reserving agents (**A**zathioprine, **R**ituxim**a**b, **M**ycophenolate, **I**ntravenous **I**mmunoglobulin, **N**icotinamide, **G**old salts). ### Why Dapsone Is Not First-Line **Warning:** Dapsone is effective in BP but is typically reserved for: - Patients with contraindications to corticosteroids - Steroid-dependent disease - Adjunctive therapy, not monotherapy - Requires baseline G6PD testing and regular hemoglobin monitoring Dapsone is more commonly first-line in **dermatitis herpetiformis** (IgA-mediated), not BP. ### Why Azathioprine Alone Is Inadequate **Key Point:** Azathioprine has a slow onset of action (4–8 weeks) and is used as a **steroid-sparing agent** after initial control with corticosteroids, not as monotherapy for active disease. [cite:Robbins 10e Ch 25; Harrison 21e Ch 297]